BrightEdge is the innovation, impact investment and venture capital arm of the American Cancer Society. Today, our ACS Impact Venture Fund (AIVF) invests in for-profit, early-stage companies developing cutting-edge, cancer-focused therapeutics, diagnostics, devices, and technologies to fuel and accelerate ACS’s mission of ending cancer as we know it, for everyone.
The Foundation’s local impact investing program allows the Foundation to:
• Develop a new tool that can promote community development;
• Broaden the community’s existing perception of the Foundation – as a community leader and grant maker – to include its new role as investor;
• Activate more existing assets and develop opportunities for residents and partners to leverage capital in support of local projects.
